Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Moodys
Dow
Colorcon
Johnson and Johnson

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Granisetron - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic sources for granisetron and what is the scope of freedom to operate?

Granisetron is the generic ingredient in six branded drugs marketed by Kyowa Kirin, Heron Theraps Inc, Akorn Inc, Aurobindo Pharma Ltd, Baxter Hlthcare Corp, Bionpharma Inc, Cipla Ltd, Dr Reddys, Fresenius Kabi Usa, Hikma Farmaceutica, Luitpold, Mylan Asi, Mylan Labs Ltd, Sandoz Inc, Teva Pharms Usa, West-ward Pharms Int, Wockhardt Usa, Roche, Pediatrx, Apotex Inc, Barr, Chartwell Molecular, Dr Reddys Labs Ltd, Epic Pharma Llc, Mylan, Natco Pharma, Orchid Hlthcare, Taro, and Teva Pharms, and is included in fifty NDAs. There are eight patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Granisetron has fifty-seven patent family members in thirty-two countries.

There are twenty-six drug master file entries for granisetron. Two suppliers are listed for this compound.

Drug Prices for granisetron

See drug prices for granisetron

Recent Clinical Trials for granisetron

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Heron TherapeuticsPhase 2
University of Alabama at BirminghamPhase 2
Northwell HealthPhase 1/Phase 2

See all granisetron clinical trials

Recent Litigation for granisetron

Identify potential future generic entrants

District Court Litigation
Case NameDate
Prostrakan, Inc. v. Actavis Laboratories UT, Inc.2016-01-15
ProStrakan, Inc. v. Actavis Laboratories UT, Inc.2016-01-13

See all granisetron litigation

Pharmacology for granisetron
Medical Subject Heading (MeSH) Categories for granisetron
Synonyms for granisetron
1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-indazole-3-carboxamide
1-Methyl-N-(9-methyl-endo-9-azabicyclo(3.3.1)non-3-yl)-1H-indazole-3-carboxamide
1-Methyl-N-[(1r,5s)-9-Methyl-9-Azabicyclo[3.3.1]nonan-3-Yl]indazole-3-Carboxamide
1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]-3-indazolecarboxamide
1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]indazole-3-carboxamide
1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-7-yl]indazole-3-carboxamide
1-methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide
107007-99-8 (mono-hydrochloride)
109889-09-0
121061-98-1
124998-65-8
1H-Indazole-3-carboxamide, 1-methyl-N-(9-methyl-9-azabicyclo(3.3.1)non-3-yl)-, endo-
3702AH
889g090
A802101
AB00918713-07
AB07494
AC-8910
AC1NR4P1
AKOS025402424
AN-7538
APF 530
APF530
API0005490
BDBM50443668
BDBM50449636
BIDD:GT0272
BRL 43694
BRL 43964
BRL-43694
C07023
CCG-221158
CHEBI:5537
CHEBI:94501
CHEMBL1290003
D04370
DB00889
DL-166
DTXSID0023111
FT-0626805
Granisetron (JAN/USAN/INN)
Granisetron [USAN:INN:BAN:JAN]
Granisetronum
GTPL2300
HMS2089P14
HMS3715H17
Kevatril
Kevatril|||1-Methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide,
Q-101870
Sancuso
Sancuso (TN)
SCHEMBL34178
SCHEMBL4890
SCHEMBL4891
SR-05000001492
SR-05000001492-1
SR-05000001492-2
Sustol
UNII-WZG3J2MCOL
VA11035
W-5139
WZG3J2MCOL
ZINC100018852
ZINC100018854
ZINC347
Paragraph IV (Patent) Challenges for GRANISETRON
Tradename Dosage Ingredient NDA Submissiondate
SANCUSO FILM, EXTENDED RELEASE;TRANSDERMAL granisetron 022198 2015-10-09

US Patents and Regulatory Information for granisetron

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Akorn Inc GRANISETRON HYDROCHLORIDE granisetron hydrochloride INJECTABLE;INJECTION 079078-002 Sep 14, 2009 AP RX No No   Start Trial   Start Trial   Start Trial
Taro GRANISETRON HYDROCHLORIDE granisetron hydrochloride TABLET;ORAL 090817-001 May 28, 2010 AB RX No No   Start Trial   Start Trial   Start Trial
Baxter Hlthcare Corp GRANISETRON HYDROCHLORIDE granisetron hydrochloride INJECTABLE;INJECTION 078198-002 Jun 30, 2008 DISCN No No   Start Trial   Start Trial   Start Trial
Bionpharma Inc GRANISETRON HYDROCHLORIDE granisetron hydrochloride INJECTABLE;INJECTION 078863-001 Jun 30, 2008 AP RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Merck
Dow
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.